Although many international locations have been selling hormonal contraceptives to stop unintended being pregnant and condom use to stop HIV transmission, little is understood about how women focused by these messages have interpreted and internalized them. We describe HIV-positive and negative women’s understanding of the advantages of contraception and condoms and their motivations to use them. This is a qualitative sub-study from a scientific trial evaluating the results of progestin contraception on HIV-positive and negative women aged 18-45 years randomly assigned to depot medroxyprogesterone acetate (DMPA) injection or levonorgestrel (LNG) implant.
We purposively recruited 41 women to take part in in-depth interviews (IDIs) and focus group discussions (FGDs) after randomization into the principle study. We carried out a complete of 30 IDIs and 6 FGDs comprised of 4-7 women (N = 32). All women had been counselled about potential dangers for HIV acquisition/transmission with progestin-only contraception, drug-drug interactions between the implant and efavirenz-based ART, and the necessity to use condoms with their assigned contraceptive to assist stop being pregnant and HIV acquisition and transmission.
All women understood that HIV is transmitted via unprotected intercourse and that HIV transmission will be prevented via condom use however not DMPA injection or LNG implant use. Nearly all HIV-positive women knew or suspected that their companions had been additionally HIV-positive and had been most in utilizing condoms to stop an infection with a drug-resistant HIV pressure to preserve their HIV viral load low. Almost all reported that their companions agreed to condom use, however few used them constantly. Most women believed that condoms had been efficient at stopping each HIV and being pregnant if used constantly.
Nearly all women thought of contraception and condom use as essential in stopping unintended being pregnant and HIV as a result of associate disclosure of HIV standing is low. Our outcomes confirmed that each HIV-positive and negative women understood modes of HIV transmission and prevention and had been conscious that hormonal contraceptives are solely efficient for stopping being pregnant and not HIV. Although each HIV-negative and constructive women had been motivated to use condoms to stop each HIV acquisition and an infection with different HIV strains respectively, all of them confronted challenges from their companions in utilizing condoms constantly.
Multi-level issues for optimum implementation of long-acting injectable antiretroviral remedy to deal with individuals residing with HIV: views of well being care suppliers collaborating in part Three trials
Long-acting injectable antiretroviral remedy (LA ART) has been proven to be non-inferior to each day oral ART, with excessive affected person satisfaction and choice to oral customary of care in analysis to date, and has lately been accepted for use in the United States and Europe. This study examined the views of well being care suppliers collaborating in LA ART scientific trials on potential obstacles and options to LA ART roll-out into actual world settings. This evaluation attracts on two knowledge sources: (1) open-ended questions embedded in a structured on-line survey of 329 well being care suppliers collaborating in the ATLAS-2 M trial throughout 13 international locations; and (2) in-depth interviews with 14 suppliers collaborating in FLAIR/ ATLAS/ATLAS-2 M trials in the United States and Spain.
Barriers and proposed options to LA ART implementation had been recognized on the particular person, clinic and well being system ranges. Provider perceptions of affected person stage obstacles included challenges with adhering to frequent injection appointments and injection tolerability. Proposed options included affected person training, having designated workers for clinic go to retention, and clinic flexibility with appointment scheduling. The most important supplier concern was figuring out applicable candidates for LA ART; proposed options centered on affected person supplier communication and choice making. Clinic stage obstacles included the necessity for added expert people to administer injections, shifts in workflow as demand will increase and the logistics of cold-chain storage.
Proposed options included workers hiring and coaching, strategic planning round workflow and logistics, and the potential of providing injections in different settings, together with the house. Health system stage obstacles included price and approvals from nationwide regulatory our bodies. Potential options included governments subsidizing therapy, guaranteeing price is aggressive with oral ART, and providing co-pay help. Results counsel the significance of multi-level assist techniques to optimize patient-provider communication and therapy decision-making; clinic staffing, workflow, logistics protocols and infrastructure; and cost-related elements inside a given well being system.
Using Incentives and Nudging to Improve Non-Targeted HIV Testing in Ecuador: A Randomized Trial
Under-detection of HIV/AIDS nonetheless burdens many low- and middle-income international locations (LMICs). Our randomized trial investigated the results of economic incentives and a behavioral nudge to induce HIV testing and studying HIV standing in Ecuador. In the management group, 12.2% of members agreed to testing, and 5.3% discovered outcomes. A monetary incentive paid at testing elevated the fraction of members examined by 50.1 share factors (95% CI 38.8 to 61.4) and the fraction who discovered their standing by 8.9 share factors (95% CI 5.3 to 12.5); the nudge had no impact.
 LDH-Cytotoxicity Colorimetric Assay Kit II |
|
K313-500 |
Biovision |
|
EUR 419 |
|
LDH-Cytotoxicity Colorimetric Assay Kit II |
|
K2027-500 |
ApexBio |
500 assays |
EUR 418 |
 LDH Cytotoxicity Assay Kit |
|
55R-1366 |
Fitzgerald |
400 assays |
EUR 519 |
|
Description: Assay Kit for detection of LDH Cytotoxicity in the research laboratory |
|
LDH Cytotoxicity Assay Kit |
|
55R-1368 |
Fitzgerald |
500 assays |
EUR 570 |
|
Description: Assay Kit for detection of LDH Cytotoxicity in the research laboratory |
|
LDH Cytotoxicity Assay Kit |
|
K6330400 |
Cusabio |
400 assays |
EUR 306 |
|
Description: Premade ready to use kits will always come in handy. Get your experiment done right form the first try by using a validated kit with perfectly balanced reagents proportions and compatibility and by following a clear protocol. |
 CytoSelect LDH Cytotoxicity Assay Kit |
|
CBA-241 |
Cell Biolabs |
960 assays |
EUR 403 |
|
Description: Cell Biolabs? CytoSelect LDH Cytotoxicity Assay Kit provides a colorimetric format for measuring and monitoring cell cytotoxicity. The kit contains sufficient reagents for the evaluation of 960 assays in 96-well plates. Cells can be plated and then treated with compounds or agents that affect cell viability. Upon cell death, lactate dehydrogenase (LDH), a soluble enzyme found in the cytoplasm, is released into the growth media. The growth media is then transferred to another plate and the released LDH is then detected with cytotoxicity reagent. In the presence of lactate substrate (included in the LDH Cytotoxicity Reagent) LDH converts lactate to pyruvate and generates nicotinamide adenine dinucleotide (NADH). The WST-1 molecule, also present in the LDH Cytotoxicity Reagent, is converted from WST-1 to the orange formazan form. An increase in cell cytotoxicity is accompanied by increased LDH release and increased colorimetric signal. The assay principles are basic and can be applied to most eukaryotic cell lines, including adherent and non-adherent cells and certain tissues, depending on LDH expression levels. The LDH Cytotoxicity Reagent can be used to detect cytotoxicity in bacteria, yeast, fungi, protozoa as well as cultured mammalian and piscine cells. |
 PicoProbe? LDH-Cytotoxicity Fluorometric Assay Kit |
|
K314-500 |
Biovision |
|
EUR 419 |
) QuantiChrom? LDH Cytotoxicity Assay Kit (C2LD-100) |
|
C2LD-100 |
Cusabio |
100 |
EUR 127.43 |
- Sample volume: 50-100ul
- Detection wavelength: 450nm
- Assay performance time: 1 to 4 hours.
|
|
Description: Quantitative determination of cytotoxicity based on cellular lactate dehydrogenase release into cell culture medium by colorimetric (565nm) method. Procedure: 30 min. Kit size: 100 tests. Detection limit: 2 U/L. Shelf life: 6 months. Shipping: ambient tem |
 Caspase-5 Colorimetric Assay Kit |
|
K2196-400 |
ApexBio |
400 assays |
EUR 1156 |
 Caspase-10 Colorimetric Assay Kit |
|
K2197-400 |
ApexBio |
400 assays |
EUR 1114 |
 Caspase-4 Colorimetric Assay Kit |
|
K2199-400 |
ApexBio |
400 assays |
EUR 1114 |
 Caspase-8 Colorimetric Assay Kit |
|
K2013-400 |
ApexBio |
400 assays |
EUR 1086 |
 Caspase-6 Colorimetric Assay Kit |
|
K2015-400 |
ApexBio |
400 assays |
EUR 1101 |
 Caspase-2 Colorimetric Assay Kit |
|
K2017-400 |
ApexBio |
400 assays |
EUR 1156 |
 Caspase-9 Colorimetric Assay Kit |
|
K2019-400 |
ApexBio |
400 assays |
EUR 1156 |
|
Caspase-8 Colorimetric Assay Kit |
|
K113-400 |
Biovision |
|
EUR 958 |
|
Caspase-6 Colorimetric Assay Kit |
|
K115-400 |
Biovision |
|
EUR 958 |
|
Caspase-2 Colorimetric Assay Kit |
|
K117-400 |
Biovision |
|
EUR 958 |
 Caspase-3 Colorimetric Assay Kit |
|
K2008-400 |
ApexBio |
400 assays |
EUR 1086 |
 Caspase-1 Colorimetric Assay Kit |
|
K2011-400 |
ApexBio |
400 assays |
EUR 1086 |
|
Caspase-3 Colorimetric Assay Kit |
|
K106-400 |
Biovision |
|
EUR 958 |
|
Caspase-5 Colorimetric Assay Kit |
|
K123-400 |
Biovision |
|
EUR 958 |
|
Caspase-10 Colorimetric Assay Kit |
|
K125-400 |
Biovision |
|
EUR 958 |
|
Caspase-4 Colorimetric Assay Kit |
|
K127-400 |
Biovision |
|
EUR 958 |
|
Caspase-9 Colorimetric Assay Kit |
|
K119-400 |
Biovision |
|
EUR 958 |
|
Caspase-1 Colorimetric Assay Kit |
|
K111-400 |
Biovision |
|
EUR 958 |
) Sulforhodamine B Cell Cytotoxicity Assay Kit (Colorimetric) |
|
K943-1000 |
Biovision |
|
EUR 316 |
) EZScreen? ATP Colorimetric Assay Kit (384-well) |
|
K959-400 |
Biovision |
|
EUR 593 |
) EZScreen? Glycogen Colorimetric Assay Kit (384-Well) |
|
K960-400 |
Biovision |
|
EUR 648 |
 Cell Meter™ Colorimetric Cell Cytotoxicity Assay Kit |
|
22780 |
AAT Bioquest |
1000 Tests |
EUR 219 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12352200
|
) EZScreen? Triglyceride Quantification Colorimetric Assay Kit (384-well) |
|
K952-400 |
Biovision |
|
EUR 626 |
) EZScreen? NAD+/NADH Colorimetric Assay Kit (384-well) |
|
K958-400 |
Biovision |
|
EUR 648 |
) EZScreen? Lactate Dehydrogenase Activity Colorimetric Assay Kit (384-well) |
|
K953-400 |
Biovision |
|
EUR 555 |
) EZScreen? Beta-Lactamase Activity Colorimetric Assay Kit (384-well) |
|
K954-400 |
Biovision |
|
EUR 729 |
) EZScreen? Free Fatty Acid Colorimetric Assay Kit (384-well) |
|
K956-400 |
Biovision |
|
EUR 648 |
 Bioluminescence Cytotoxicity Assay Kit |
|
55R-1367 |
Fitzgerald |
500 assays |
EUR 312 |
|
Description: Assay Kit for detection of Bioluminescence Cytotoxicity in the research laboratory |
 EnzyLight Cytotoxicity Assay Kit |
|
ECTX-100 |
BioAssay Systems |
100 |
EUR 275 |
|
Description: Rapid, bioluminescent luciferin/luciferase based assay for cell viability, proliferation, cytotoxcity, high-throµghput screening for anticancer agents. Procedure: 2 min. Kit size: 100 tests. Detection limit: 50 cells. Shelf life: 6 months. Shipping: on ic |
|
Bioluminescence Cytotoxicity Assay Kit |
|
K312-500 |
Biovision |
|
EUR 245 |
) EZScreen? Total Cholesterol & Cholesteryl Ester Colorimetric Assay Kit (384-Well) |
|
K957-400 |
Biovision |
|
EUR 599 |
 Assay Kit) Amplite™ Colorimetric D-Lactate Dehydrogenase (LDH) Assay Kit |
|
13809 |
AAT Bioquest |
200 Tests |
EUR 306 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12352200
|
 Assay Kit) Amplite™ Colorimetric L-Lactate Dehydrogenase (LDH) Assay Kit |
|
13813 |
AAT Bioquest |
200 Tests |
EUR 306 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12352200
|
 hydroxyproline assay kit 96-assays |
|
QZBhypro1 |
Quickzyme |
1 plate 96 assays |
EUR 323 |
 AK Bioluminescence Cytotoxicity Assay Kit |
|
K2026-500 |
ApexBio |
500 assays |
EUR 266 |
) Caspase-3 DEVD-R110 Fluorometric and Colorimetric Assay Kit (100 assays) |
|
30008-2 |
Biotium |
1KIT |
EUR 383 |
|
Description: Minimum order quantity: 1 unit of 1KIT |
) Caspase-8 IETD-R110 Fluorometric and Colorimetric Assay Kit (25 assays) |
|
30011-1 |
Biotium |
1KIT |
EUR 204 |
|
Description: Minimum order quantity: 1 unit of 1KIT |
) Caspase-8 IETD-R110 Fluorometric and Colorimetric Assay Kit (100 assays) |
|
30011-2 |
Biotium |
1KIT |
EUR 383 |
|
Description: Minimum order quantity: 1 unit of 1KIT |
 Acetylcholinesterase Activity Assay Kit - 100 Assays |
|
AR4001-unit |
BosterBio |
unit |
EUR 317 |
) OxiSelect AOPP Assay Kit (200 assays) |
|
STA-318 |
Cell Biolabs |
200 assays |
EUR 635 |
|
Description: Advanced Oxidation Protein Products (AOPP) are uremic toxins created during oxidative stress through the reaction of plasma proteins with chlorinated oxidants such as chloramines or hypochlorous acid. AOPP levels are elevated in patients with renal complications, diabetes mellitus, and atherosclerosis, as well as HIV-positive patients. Our OxiSelect AOPP Assay Kit provides a convenient method to assess oxidative stress. The kit includes a Chloramine standard and an AOPP Human Serum Albumin conjugate for use as a positive control. |
 soluble collagen assay kit 96-assays |
|
QZBcol1-1 |
Quickzyme |
1 plate 96 assays |
EUR 334 |
 hydroxyproline assay kit 2x 96-assays |
|
QZBhypro2 |
Quickzyme |
2 plates 192 assays |
EUR 590 |
 total collagen assay kit 96-assays |
|
QZBtotcol1 |
Quickzyme |
1 plate 96 assays |
EUR 334 |
 total protein assay kit 96-assays |
|
QZBtotprot1 |
Quickzyme |
1 plate 96 assays |
EUR 288 |
) CASPASE3 DEVDR110 ASSAY (25 ASSAYS) |
|
30008-1 |
Biotium |
1KIT |
EUR 204 |
|
Description: Minimum order quantity: 1 unit of 1KIT |
 Acid Phosphatase Cell Cytotoxicity Assay Kit |
|
K937-500 |
Biovision |
|
EUR 370 |
 Neutral Red Cell Cytotoxicity Assay Kit |
|
K447-1000 |
Biovision |
|
EUR 316 |
 Crystal Violet Cell Cytotoxicity Assay Kit |
|
K329-1000 |
Biovision |
|
EUR 316 |
 EnzyChrom Kinase Assay Kit |
|
EKIN-400 |
BioAssay Systems |
400 |
EUR 297 |
|
Description: Rapid mix-and-measure procedure for determination of kinase activity and high-throµghput screening for kinase inhibitors by fluorimetric (530nm/590nm) method. Procedure: 10 min. Kit size: 400 tests. Detection limit: 0.01 U/L. Shelf life: 6 months. Shippin |
 ELISA Kit) Mouse Lactate Dehydrogenase (LDH) ELISA Kit |
|
DLR-LDH-Mu-48T |
DL Develop |
48T |
EUR 508 |
- Should the Mouse Lactate Dehydrogenase (LDH) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Lactate Dehydrogenase (LDH) in samples from serum, plasma, tissue homogenates or other biological fluids. |
|
Mouse Lactate Dehydrogenase (LDH) ELISA Kit |
|
DLR-LDH-Mu-96T |
DL Develop |
96T |
EUR 661 |
- Should the Mouse Lactate Dehydrogenase (LDH) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Lactate Dehydrogenase (LDH) in samples from serum, plasma, tissue homogenates or other biological fluids. |
|
Mouse Lactate Dehydrogenase (LDH) ELISA Kit |
|
RDR-LDH-Mu-48Tests |
Reddot Biotech |
48 Tests |
EUR 534 |
|
Mouse Lactate Dehydrogenase (LDH) ELISA Kit |
|
RDR-LDH-Mu-96Tests |
Reddot Biotech |
96 Tests |
EUR 742 |
|
Mouse Lactate Dehydrogenase (LDH) ELISA Kit |
|
RD-LDH-Mu-48Tests |
Reddot Biotech |
48 Tests |
EUR 511 |
|
Mouse Lactate Dehydrogenase (LDH) ELISA Kit |
|
RD-LDH-Mu-96Tests |
Reddot Biotech |
96 Tests |
EUR 709 |
 Activity Assay Kit) Lactate Dehydrogenase (LDH) Activity Assay Kit |
|
K2228-500 |
ApexBio |
500 assays |
EUR 529 |
) MTT Cell Viability Assay Kit (1000 assays) |
|
30006 |
Biotium |
1KIT |
EUR 204 |
|
Description: Minimum order quantity: 1 unit of 1KIT |
) Resazurin Cell Viability Assay Kit (2500 assays) |
|
30025-1 |
Biotium |
1KIT |
EUR 181 |
|
Description: Minimum order quantity: 1 unit of 1KIT |
 soluble collagen assay kit 2x 96-assays |
|
QZBcol1-2 |
Quickzyme |
2 plates 192 assays |
EUR 614 |
 soluble collagen assay kit 5x 96-assays |
|
QZBcol1-5 |
Quickzyme |
5 plates 480 assays |
EUR 1196 |
 sensitive tissue collagen assay kit 96-assays |
|
QZBtiscol1 |
Quickzyme |
1 plate 96 assays |
EUR 411 |
 total collagen assay kit 2x 96-assays |
|
QZBtotcol2 |
Quickzyme |
2 plates 192 assays |
EUR 614 |
 total protein assay kit 2x 96-assays |
|
QZBtotprot2 |
Quickzyme |
2 plates 192 assays |
EUR 527 |
 Caspase-5 Fluorometric Assay Kit |
|
K2195-400 |
ApexBio |
400 assays |
EUR 1114 |
 Caspase-4 Fluorometric Assay Kit |
|
K2198-400 |
ApexBio |
400 assays |
EUR 1114 |
 Caspase-8 Fluorometric Assay Kit |
|
K2012-400 |
ApexBio |
400 assays |
EUR 1086 |
 Caspase-6 Fluorometric Assay Kit |
|
K2014-400 |
ApexBio |
400 assays |
EUR 1086 |
 Caspase-2 Fluorometric Assay Kit |
|
K2016-400 |
ApexBio |
400 assays |
EUR 1114 |
 Caspase-9 Fluorometric Assay Kit |
|
K2018-400 |
ApexBio |
400 assays |
EUR 1114 |
|
Caspase-6 Fluorometric Assay Kit |
|
K114-400 |
Biovision |
|
EUR 958 |
|
Caspase-2 Fluorometric Assay Kit |
|
K116-400 |
Biovision |
|
EUR 958 |
|
Caspase-9 Fluorometric Assay Kit |
|
K118-400 |
Biovision |
|
EUR 958 |
 Caspase-3 Fluorometric Assay Kit |
|
K2007-400 |
ApexBio |
400 assays |
EUR 1086 |
 Caspase-1 Fluorometric Assay Kit |
|
K2010-400 |
ApexBio |
400 assays |
EUR 1086 |
|
Caspase-3 Fluorometric Assay Kit |
|
K105-400 |
Biovision |
|
EUR 979 |
 Caspase-10 Fluorometric Assay Kit |
|
K124-400 |
Biovision |
|
EUR 958 |
|
Caspase-4 Fluorometric Assay Kit |
|
K126-400 |
Biovision |
|
EUR 925 |
|
Caspase-5 Fluorometric Assay Kit |
|
K122-400 |
Biovision |
|
EUR 958 |
|
Caspase-1 Fluorometric Assay Kit |
|
K110-400 |
Biovision |
|
EUR 958 |
|
Caspase-8 Fluorometric Assay Kit |
|
K112-400 |
Biovision |
|
EUR 958 |
 Glutathione Colorimetric Assay Kit |
|
55R-1351 |
Fitzgerald |
100 assays |
EUR 706 |
|
Description: Assay Kit for detection of Glutathione activity in the research laboratory |
) Methylglyoxal Assay Kit (Colorimetric) |
|
K500-100 |
Biovision |
|
EUR 528 |
) Salicylate Assay Kit (Colorimetric) |
|
K494-100 |
Biovision |
|
EUR 544 |
 Cobalt Colorimetric Assay Kit |
|
K505-100 |
Biovision |
|
EUR 457 |
) Histamine Assay Kit (Colorimetric) |
|
K506-100 |
Biovision |
|
EUR 501 |
 Nickel Colorimetric Assay Kit |
|
K510-100 |
Biovision |
|
EUR 457 |
 Chloride Colorimetric Assay Kit |
|
K530-100 |
Biovision |
|
EUR 359 |
) Lithium Assay Kit (Colorimetric) |
|
K545-100 |
Biovision |
|
EUR 620 |
 Hydroxyproline Colorimetric Assay Kit |
|
K555-100 |
Biovision |
|
EUR 599 |
 Glutamine Colorimetric Assay Kit |
|
K556-100 |
Biovision |
|
EUR 588 |
The HIV-positive price was 1.2% in the management group, and incentives prompted a 4.7 share level (95% CI 0.5 to 8.9) increased proportion of HIV-positive detection. Incentives additionally induced earlier testing, suggesting diminished procrastination. This means that info with appropriately timed small monetary incentives can enhance HIV testing and detection of recent instances in the overall inhabitants in LMIC settings. Both assessments explored supplier views and clinic dynamics associated to the introduction of LA ART and had been analyzed utilizing thematic content material evaluation. The Consolidated Framework for Implementation Research (CFIR) was drawn on because the conceptual framework underpinning improvement of a mannequin depicting study findings.
